FDA
has issued draft guidance: Specifications for Preparing and Submitting Summary
Level Clinical Site Data for CDER’s Inspection Planning, which provides current
FDA specifications for preparing and submitting a summary-level clinical-site
dataset in electronic form for NDAs, BLAs, and NDA or BLA supplemental
applications submitted to FDA’s CDER.
Posted by Tim Sandle
No comments:
Post a Comment
Pharmaceutical Microbiology Resources